Regeneron Pharmaceuticals' Operating Income fell 1113.92% to $879.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.6 billion, marking a year-over-year decrease of 1034.4%. This contributed to the annual value of $3.6 billion for FY2025, which is 1034.4% down from last year.
Latest data reveals that Regeneron Pharmaceuticals reported Operating Income of $879.9 million as of Q4 2025, which was down 1113.92% from $1.0 billion recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Operating Income ranged from a high of $3.3 billion in Q2 2021 and a low of $591.7 million during Q1 2025
Its 5-year average for Operating Income is $1.3 billion, with a median of $1.1 billion in 2022.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Operating Income soared by 40993.3% in 2021, and later crashed by 6684.09% in 2022.
Over the past 5 years, Regeneron Pharmaceuticals' Operating Income (Quarter) stood at $2.6 billion in 2021, then crashed by 56.56% to $1.1 billion in 2022, then decreased by 15.16% to $972.9 million in 2023, then increased by 1.78% to $990.2 million in 2024, then dropped by 11.14% to $879.9 million in 2025.
Its Operating Income was $879.9 million in Q4 2025, compared to $1.0 billion in Q3 2025 and $1.1 billion in Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value